The UK’s Medicines Discovery Catapult and the Medical Research Council (MRC) Centre for Drug Safety Science (CDSS) are collaborating to advance human-based drug evaluation.
Together, the two organisations aim to pool their collective academic and industry experience to develop next-generation 3D human cell models and create robust cellular programmes.
The innovations arising from this collaboration will be available to drug discovery SMEs in the UK.
The purpose of the collaboration is to identify and establish projects focused on the development of human 3D cell models and robust cellular platforms.
Next-gen 3D cell models will provide even better predictive and patient relevant data by mimicking human tissue architecture, microenvironment, and signalling.
The first project to be undertaken under the new alliance will focus on the development of a next generation cardiac safety model. The human cell model will enable companies to measure a broader range of patient relevant toxicities in a single assay.
Cell models will be jointly identified, fully characterised, optimised, industry-validated and made available to UK SMEs at the Medicines Discovery Catapult.
As the partnership develops it will combine the cell biology and pharmacology expertise of CDSS with Medicines Discovery Catapult’s organ-on-a-chip capabilities and know-how, to explore ground-breaking opportunities to connect together multiple organ models to further improve patient relevance.